Dantrolene availability
/
The EMHG has published guidelines on the availability of dantrolene:
Recommendations
In addition to the guidelines for MH diagnosis the European Malignant Hyperthermia Group has issued the following recommendations. Previous recommendations can be found here.
Featured
The EMHG has produced a guideline on MH during pregnancy using a two-round Delphi consensus process.
Questions arising in regard to MH-susceptibility:
Should MH-susceptibility as clinically proven in a proband and/or predictive data (IVCT and/or genetic tests) be reported by the applicant to the insurer?
as underwriting requires applicants to give an accurate and complete description of the risk characteristics to be covered (‘good faith’ concept – ‘legal duty’ in most European countries)
recognizing the insurer’s legitimate interest in assessing the level of risk presented by the insured person (actuarial fairness)
but being in conflict with the right of privacy and self-determination (and the right not to know) Convention on Human Rights and Biomedicine (ETS 164, Oviedo, 04.04.1997).
Can MH-susceptibility lead to in an increase of the premium?
Can MH-susceptiblity limit the liability of the insurer? Could it lead to termination of insurance? Can it lead to any total or partial exclusion from insurance?
Do you as a professional have to (or can you) warn other family members of the risk of MH?
Can you as a professional be asked to communicate to the insurer information from the patient’s medical file with his/her consent?.
Anaesthetic management in MH suspected or susceptible patients. The preparation of the workstation is covered in the next recommendation.
